Skip to main content
TipRanks
Go Ultimate75% OFF

Evaxion Biotech (EVAX) Stock Price & Analysis

435 Followers

EVAX Stock Chart & Stats

$2.77$0.03(1.09%)
At close: 4:00 PM EST
$3$3.5$4Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$2.74 - $2.89
52-Week Range
$2.65 - $6.92
Previous Close
$2.74
Volume
N/A
Average Volume (3M)
109.19K
Market Cap
$22.85M
Enterprise Value
$18.96M
Total Cash (Recent Filing)
$14.00M
Total Debt (Recent Filing)
$7.10M
Price to Earnings (P/E)
―
Beta
2.14
Next Earnings
Nov 19, 2026 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Durable EVX-01 Clinical Responses

Durable three-year responses and sustained immune activity strengthen EVX-01’s clinical profile beyond an initial readout. This supports the credibility of Evaxion’s personalized vaccine approach, improves partnering potential, and provides a foundation for advancing the lead oncology asset.

AI-Immunology Platform Validation

External recognition of the AI-Immunology platform adds scientific credibility to Evaxion’s technology and may improve visibility with partners. Platform validation is potentially durable because the same discovery capabilities support multiple oncology, infectious-disease, and autoimmune programs.

Broader Pipeline And Strategic Reach

Expansion into glioblastoma broadens Evaxion’s opportunity set beyond its lead melanoma program and applies its antigen-discovery platform to another high-unmet-need cancer. The Duke collaboration also adds specialized clinical expertise for development of EVX-05.

Bears Say

Persistent Unprofitable Operations

Continued losses and no reported revenue show that Evaxion has not yet established a self-sustaining commercial model. Ongoing R&D investment is necessary for pipeline progress, but the absence of operating profitability leaves earnings dependent on future clinical and business-development success.

Negative Cash Generation And Funding Dependence

Persistent negative operating and free cash flow means the company cannot currently fund development from internal operations. Continued cash consumption increases reliance on financing or partnerships, leaving future program execution sensitive to capital availability and funding conditions.

Equity Financing And Development Uncertainty

Recent ATM issuance provides funding but expands the share base and can dilute existing holders. At the same time, important programs remain preclinical or dependent on regulatory and CMC milestones, making the timing and value of future pipeline progress uncertain.

Evaxion Biotech News

EVAX FAQ

What was Evaxion Biotech’s price range in the past 12 months?
Evaxion Biotech lowest stock price was $2.65 and its highest was $6.92 in the past 12 months.
What is Evaxion Biotech’s market cap?
Evaxion Biotech’s market cap is $22.85M.
When is Evaxion Biotech’s upcoming earnings report date?
Evaxion Biotech’s next earnings report is estimated for Nov 19, 2026 (not yet confirmed), which is in 2 days.
How were Evaxion Biotech’s earnings last quarter?
Evaxion Biotech released its earnings results on Aug 20, 2026. The company reported -$0.01 earnings per share for the quarter.
Is Evaxion Biotech overvalued?
According to Wall Street analysts Evaxion Biotech’s price is currently Undervalued.
Does Evaxion Biotech pay dividends?
Evaxion Biotech does not currently pay dividends.
What is Evaxion Biotech’s EPS estimate?
Evaxion Biotech’s EPS estimate is -0.01.
How many shares outstanding does Evaxion Biotech have?
Evaxion Biotech has 8,340,215 shares outstanding.
What happened to Evaxion Biotech’s price movement after its last earnings report?
Evaxion Biotech reported an EPS of -$0.01 in its last earnings report. Following the earnings report the stock price went up 4.127%.
Which hedge fund is a major shareholder of Evaxion Biotech?
Hedge funds hold Evaxion Biotech shares: the largest hedge-fund position in Evaxion Biotech is 62,975,851 shares, and hedge funds decreased their holdings by 10.1K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology